FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
Viking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).
"During the first quarter, we made continued progress on our Phase 2b VOYAGE clinical trial evaluating VK2809 in patients with biopsy-confirmed NASH and fibrosis," stated Brian Lian, Ph.D., chief... More

